Skip to main content
SpringerLink
Log in

Botulinum toxin in children with cerebral palsy

  • Special Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Botulinum toxin is a neurotoxin that blocks the synaptic release of acetylcholine from cholinergic nerve terminals mainly at the neuromuscular junction, resulting in irreversible loss of motor end plates. It is being widely tried as a targeted antispasticity treatment in children with cerebral palsy. A number of studies have shown that it reduces spasticity and increases the range of motion and is particularly useful in cases with dynamic contractures. However improvement in function has not been convincingly demonstrated. It is an expensive mode of therapy and the injections need to be repeated after 3–6 months. Whereas Botulinum toxin can be a valuable adjunct in select cases, it should not be projected as a panacea for children with spastic cerebral palsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davies LE. Botulinum toxin: from poison to medicine.Western J Med 1993; 158: 25–29.

    Google Scholar 

  2. Burgen ASV, Dickens F, Zatinam LJ. The action of botulinum toxin on the neuromuscular junction.J Physiol 1949; 109: 10–24.

    PubMed  CAS  Google Scholar 

  3. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.Proc Natl Acad Sci USA 1999; 96: 3200–3205.

    Article  PubMed  Google Scholar 

  4. van Ermengen E. Uber einen neuen anaeroben bacillus and seine beziehungen zum botulismus.Z Hyg Infektionskrank 1897; 26: 1–56. (In German)

    Article  Google Scholar 

  5. Scott AB, Rosenbaum A, Collins CC. Pharmacological weakening of extraocular muscles.Invest Opthalmol Vis Sci 1973; 12: 924–927.

    CAS  Google Scholar 

  6. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus.Trans Am Ophthalmol Soc 1981; 79:734–770.

    PubMed  CAS  Google Scholar 

  7. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications.Muscle Nerve 1997; (Suppl 6): S 125-S 145.

  8. Brin MF. Botulinum toxin: new and expanded indications.Eur J Neurol 1997; 4: S 59-S 65.

    Google Scholar 

  9. Verheyden J, Blitzer A. Other noncosmetic uses of BOTOX.Dis Mon 2002; 48: 357–366.

    Article  PubMed  Google Scholar 

  10. Middlebrook JL. Cell surface receptors for protein toxins. In: Simpson LL, ed.Botulinum Neurotoxin and Tetanus Toxin. Academic Press, San Diego, 1989; 95–119.

    Google Scholar 

  11. Shaari CM, George E, Wu, BL Wu, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia.Laryngoscope 1991; 101: 960–964.

    Article  PubMed  CAS  Google Scholar 

  12. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli Pet al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.Nature 1993; 365: 160–163.

    Article  PubMed  CAS  Google Scholar 

  13. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MSet al. Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management.JAMA 2001; 285: 1059–1070.

    Article  PubMed  CAS  Google Scholar 

  14. Simpson LL. Botulinum toxin: potent poison, potent medicine.Hosp Pract 1999; 34: 87–91.

    CAS  Google Scholar 

  15. Hambleton P, Cohen HE, Palmer J, Melling J. Antitoxins and botulinum toxin treatment.BMJ 1992; 304: 959–960

    PubMed  CAS  Google Scholar 

  16. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single fibre EMG studies.Neurology 1986; 36: 545–547.

    PubMed  CAS  Google Scholar 

  17. Hagberg B, Hagberg G. Origin of cerbral palsy. In David TJet al., eds.Recent Advances in Pediatrics. No.11. London: Churchill Livingston 1999: 67–83.

    Google Scholar 

  18. Dabney KW, Lipton GE, Miller F. Cerebral palsy.Curr Opin Pediatr 1997; 9: 81–88.

    Article  PubMed  CAS  Google Scholar 

  19. Roman LA, Smith BP, Shilt JS. Cerebral palsy.Lancet 2004; 363: 1619–1631.

    Article  Google Scholar 

  20. Gage JR. Clinics in developmental medicine, No.121. Gait analysis in cerebral palsy, Oxford: Mackeith Press, 1991.

    Google Scholar 

  21. Smith MF. Advances in the management of cerebral palsy. In David TJ, ed.Recent Advances in Pediatrics, No. 17. London: Churchill Livingstone, 1999: 129–140.

    Google Scholar 

  22. Hainsworth F, Harrison MJ, Sheldon TA, Roussounis SH. A preliminary evaluation of ankle orthoses in the management of children with cerebral palsy.Dev Med Child Neurol 1997; 39: 243–247.

    Article  PubMed  CAS  Google Scholar 

  23. Diamond M. Rehabilitation strategies for the child with cerebral palsy.Pediatr Ann 1986; 15: 230–234.

    PubMed  CAS  Google Scholar 

  24. Botte MJ, Abrams RA, Bodine-Fowler SC. Treatment of acquired muscle spasticity using phenol peripheral nerve blocks.Orthopedics 1995; 18: 151–159.

    PubMed  CAS  Google Scholar 

  25. Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response.Dev Med Child Neurol 1999; 41: 226–232.

    Article  PubMed  CAS  Google Scholar 

  26. Eames NW, Baker R, Cosgrove A. Defining gastrocnemius muscle length in ambulant children.Gait Posture 1997; 6: 9–17.

    Article  Google Scholar 

  27. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation.J Pediatr Orthop 1993; 13: 489–495.

    PubMed  CAS  Google Scholar 

  28. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin A in the management of children with cerebral palsy: a systematic review.Eur J Neurol 1993; 8: 1–20.

    Article  Google Scholar 

  29. Koman LA, Mooney JF 3rd, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum A toxin: report of a preliminary, randomized, double-blind trial.J Pediatr Orthop 1994; 14: 299–303.

    PubMed  CAS  Google Scholar 

  30. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr Let al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double blind, placebo-controlled, dose-ranging study.Dev Med Child Neurol 2002; 44: 666–675.

    Article  PubMed  CAS  Google Scholar 

  31. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.Arch Dis Child 2000; 83: 481–487.

    Article  PubMed  CAS  Google Scholar 

  32. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a doubleblind trial.Dev Med Child Neurol 1997; 39: 185–193.

    Article  PubMed  CAS  Google Scholar 

  33. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy.J Pediatr 2000; 137: 331–337.

    Article  PubMed  CAS  Google Scholar 

  34. Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass Get al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial.Dev Med Child Neurol 2000; 42: 116–121.

    Article  PubMed  CAS  Google Scholar 

  35. Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Muller Jet al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of high-dose versus low-dose treatment.Neuropediatrics 1999; 30: 120–124.

    PubMed  CAS  Google Scholar 

  36. Polak F, Morton R, Ward C, Wallace WA, Doderlein L, Siebel A. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.Dev Med Child Neurol 2002; 44: 551–555.

    Article  PubMed  Google Scholar 

  37. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.J Pediatr Orthop 1998; 18: 304–311.

    Article  PubMed  CAS  Google Scholar 

  38. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy.J Paediatr Child Health 1999; 35: 71–77.

    Article  PubMed  CAS  Google Scholar 

  39. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, Eyssen M, Pauwels P, De Cock P. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures.Eur J Neurol 2001; 8: 75–87.

    Article  PubMed  Google Scholar 

  40. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients.Neurosci Lett 1995; 201: 37–40.

    Article  PubMed  CAS  Google Scholar 

  41. Detrembleur C, Lejeune TM, Renders A, van Den Bergh PY. Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy.Mov Disord 2002; 17: 162–169.

    Article  PubMed  CAS  Google Scholar 

  42. Boyd RN, Dobson F, Parrott J, Love S, Oates J, Larson Aet al. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial.Eur J Neurol 2001; 8: 109–119.

    Article  PubMed  Google Scholar 

  43. Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.Pediatr Drugs 2003; 5: 11–23.

    Google Scholar 

  44. Ade-Hall RA, Moore AP. Botulinum toxin type A in the treatment of lower limb spasticity in CP (Cochrane Review) InThe Cochrane Library, Issuel. Chichester, UK: John Wiley and Sons. 2004.

    Google Scholar 

  45. Boyd RN, Graham HK. Botulinum toixn A in the management of children with cerebral palsy: indications and outcome.Eur J Neurol 1997; 4: S 15-S 22.

    Google Scholar 

  46. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJet al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.Gait Posture 2000; 11: 67–79.

    Article  PubMed  CAS  Google Scholar 

  47. Carr LJ, Cosgrove AP, Gringras P, Neville BG. Position paper on the use of botulinum toxin in cerebral palsy.Arch Dis Child 1998; 79: 271–273.

    Article  PubMed  CAS  Google Scholar 

  48. Gormley ME, Gaebler-Spira D, Delgado MR. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a threecenter retrospective chart review.J Child Neurol 2001; 16: 113–118.

    Article  PubMed  CAS  Google Scholar 

  49. O’Brien CF. Treatment of spasticity with botulinum toxin.Clin J Pain 2002; 18: S 182-S 190.

    Article  Google Scholar 

  50. Schwerin A, Berweck S, Fietzek UM, Heinen F. Botulinum toxin B treatment in children with spastic movement disorders: A pilot study.Pediatr Neurol 2004; 31: 109–113.

    Article  PubMed  Google Scholar 

  51. Brin MF, Lew MF, Adler CH, Cornelia CL, Factor SA, Jankovic Jet al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology 1999; 53: 1431–1438. 52. Montecucco C, Schiavo G, Tugnoli V, de Grandis D. Botulinum neurotoxins: mechanism of action and therapeutic applications.Mol Med Today 1996; 2: 418–424.

    PubMed  CAS  Google Scholar 

  52. Naumann M, Jankovic J. Safety of Botulinum toxin type A: A systematic review and meta-analysis.Curr Med Res Opin 2004; 20: 981–990.

    Article  PubMed  CAS  Google Scholar 

  53. Brashear A, Lew MF, Dykstra DD, Cornelia CL, Factor SA, Rodnitzky RLet al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.Neurology 1999; 53: 1439–1446.

    PubMed  CAS  Google Scholar 

  54. Dressler D, Benecke R. Initial experienceswith clinical use of botulinum toxin type BNervenarzt 2002; 73:194–198.

    Article  PubMed  CAS  Google Scholar 

  55. Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Secondary nonresponse due to development of neurtralising antibodies to Botulinum toxin A during treatment of children with cerebral palsy.Neuropediatrics 2000; 31: 333–334.

    Article  PubMed  CAS  Google Scholar 

  56. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group.J Neurol 1999; 246: 265–274.

    Article  PubMed  CAS  Google Scholar 

  57. Tilton AH. Management of spasticity in children with cerebral palsy.Semin Pediatr Neurol 2004; 11: 58–65.

    Article  PubMed  Google Scholar 

  58. Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerbral palsy)Mov Disord 2004; 19: S162-S 167.

    Google Scholar 

  59. Jefferson RJ. Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 2004; 46: 491–499.

    Article  PubMed  Google Scholar 

  60. Pidcock FS. The emerging role of therapeutic botulinum toxin in the treatment of cerebral palsy.J Pediatr 2004; 145: S33-S35.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advanced Pediatrics Centre, Postgraduate Institute of Medical Sciences, 160012, Chandigarh, India

    Pratibha Singhi (Professor,Chief Pediatric Neurology and Neurodevelopment) & Munni Ray

Authors
  1. Pratibha Singhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Munni Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pratibha Singhi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singhi, P., Ray, M. Botulinum toxin in children with cerebral palsy. Indian J Pediatr 71, 1087–1091 (2004). https://doi.org/10.1007/BF02829820

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02829820

Key words

Search

Navigation